These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25818126)

  • 1. A 78-year-old woman with brain metastases.
    Tafe LJ; Tsongalis GJ
    Clin Chem; 2015 Apr; 61(4):584-6. PubMed ID: 25818126
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma.
    Tao H; Cai Y; Shi L; Tang J; Liu Z; Wang Z; Bai L; Liu Z
    Thorac Cancer; 2017 Jan; 8(1):8-15. PubMed ID: 27779369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma.
    Muscarella LA; Trombetta D; Fabrizio FP; Scarpa A; Fazio VM; Maiello E; Rossi A; Graziano P
    J Thorac Oncol; 2017 Oct; 12(10):e161-e163. PubMed ID: 28939148
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement.
    Khozin S; Roth MJ; Rajan A; Smith K; Thomas A; Berman A; Giaccone G
    J Thorac Oncol; 2012 Nov; 7(11):e29-31. PubMed ID: 23070248
    [No Abstract]   [Full Text] [Related]  

  • 5. High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients.
    Zhang Z; Ye S; Zhang M; Wu J; Yan H; Li X; He J
    Tumour Biol; 2017 Jul; 39(7):1010428317720212. PubMed ID: 28720066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases.
    Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):406-413. PubMed ID: 27598807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.
    Zhao N; Zheng SY; Yang JJ; Zhang XC; Xie Z; Xie B; Su J; Chen ZH; Chen SL; Zhang N; Lou NN; Dong S; Wu YL
    Clin Lung Cancer; 2015 Mar; 16(2):e5-9. PubMed ID: 25496960
    [No Abstract]   [Full Text] [Related]  

  • 8. Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma.
    Su YL; Rau KM
    J Thorac Oncol; 2015 Apr; 10(4):e21-2. PubMed ID: 25789840
    [No Abstract]   [Full Text] [Related]  

  • 9. Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?
    Wang TJ; Saad S; Qureshi YH; Jani A; Nanda T; Yaeh AM; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Lesser J; Halmos B; Stoopler MB; Lassman AB; Cheng SK; Isaacson SR
    Neuro Oncol; 2015 Jul; 17(7):1022-8. PubMed ID: 25910841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer.
    Baik CS; Chamberlain MC; Chow LQ
    J Thorac Oncol; 2015 Sep; 10(9):1268-1278. PubMed ID: 26107553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung.
    Shi M; Xu H; DiPoto Brahmbhatt A; Gonzalez-Toledo E; Georgescu MM
    Am J Case Rep; 2018 Jan; 19():99-104. PubMed ID: 29371584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.
    Choi CM; Kim MY; Hwang HJ; Lee JB; Kim WS
    Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.
    Rusthoven CG; Doebele RC
    J Clin Oncol; 2016 Aug; 34(24):2814-9. PubMed ID: 27298405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain metastases from early stage endometrial carcinoma 8 years after primary treatment: case report and review of the literature.
    Lee WJ; Chen CH; Chow SN
    Acta Obstet Gynecol Scand; 2006; 85(7):890-1. PubMed ID: 16817094
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to pemetrexed rechallenge after acquired resistance of ALK inhibitors.
    Miyazaki K; Satoh H; Tamura T
    Lung Cancer; 2016 Dec; 102():135. PubMed ID: 27526980
    [No Abstract]   [Full Text] [Related]  

  • 17. Cortical visual loss consequent to brain metastases from an endometrial carcinoma.
    Al-Mujaini A; Gans M; Deschênes J
    Can J Ophthalmol; 2008 Aug; 43(4):486. PubMed ID: 18711472
    [No Abstract]   [Full Text] [Related]  

  • 18. Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies.
    Kobayashi Y; Sakao Y; Ito S; Park J; Kuroda H; Sakakura N; Usami N; Mitsudomi T; Yatabe Y
    J Thorac Oncol; 2013 Aug; 8(8):e75-8. PubMed ID: 23857406
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse metastases of lung adenocarcinoma with EGFR mutation.
    Kunimasa K; Masuda G; Watanabe N; Ishida T
    Intern Med; 2012; 51(6):685-6. PubMed ID: 22449692
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.